Skip to Content

Fulcrum Therapeutics, Inc.

Securities Class Action

  • Date:
  • 4/28/2023
  • Company Name:
  • Fulcrum Therapeutics, Inc.
  • Stock Symbol:
  • FULC
  • Class Period:
  • FROM 3/3/2022 TO 3/8/2023
  • Status:
  • Filed
  • Filing Date:
  • 4/28/2023
  • Court:
  • U.S. Bankruptcy Court: District of New Jersey

Case Finder

Locate any case using the tools below.

Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Fulcrum Therapeutics, Inc. (“Fulcrum” or the “Company”) (NASDAQ: FULC) in the United States District Court for the District of New Jersey on behalf of all persons and entities who purchased or otherwise acquired Fulcrum securities between March 3, 2022 and March 8, 2023, both dates inclusive (the “Class Period”). Investors have until June 27, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Throughout the Class Period, Defendants made materially false and misleading statements regarding the Company’s business, operations, and compliance policies. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (i) the preclinical data submitted in support of FTX-6058 showed safety concerns regarding potential hematological malignancies; (ii) the foregoing safety concerns increased the likelihood that the FDA would place a clinical hold on preclinical studies of FTX-6058; (iii) accordingly, the Company had overstated FTX-6058’s clinical and/or commercial prospects; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

If you purchased or otherwise acquired Fulcrum shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Melissa Fortunato by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out the form below.  There is no cost or obligation to you.
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Fulcrum Therapeutics. BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: